Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B002 in HER2-positive Recurrent or Metastatic Breast Cancer
NCT04382352Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B 002 in HER2-positive breast cancer, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Maximum Tolerated Dose at 21 days and Dose-Limiting Toxicity at 21 days. Started May 2019; status: completed.
02
Drugs
B 002
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04382352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382352.